23andMe and the non-profit Sickle Cell 101, have joined forces to expand awareness of people’s sickle cell carrier status. The collaboration will include DNA testing and access to 23andMe’s Health + Ancestry Service for up to 1,000 eligible participants, and 23andMe will be providing monetary support to Sickle Cell 101 to support this effort.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ME:
- 23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
- 23andME (NASDAQ:ME) Rises on FDA Approval to Report Additional Gene Variants
- 23andMe cleared by FDA to report additional BRCA variants
- 23andMe Granted New FDA Clearance to Report Additional BRCA Variants
- 23andMe price target lowered to $1.75 from $2.50 at Citi